What You Don't Know About GlucoFull Supplements Could Be Costing To More Than You Think
Introduction:
Glucose metabolism disorders have become one of the leading causes of morbidity and mortality worldwide. Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Managing T2DM requires lifestyle modifications, oral hypoglycemic medications, and GlucoFull Blood Sugar insulin therapy. Recently, a dietary supplement called GlucoFull has gained popularity for its potential to regulate blood sugar levels and improve glycemic control. This case study aimed to investigate the effects of GlucoFull on glycemic control in individuals with T2DM.
Methods:
This case study was a prospective, open-label design. Thirty participants with untreated T2DM were recruited from a primary care clinic. Participants had a body mass index (BMI) of 25-40 kg/m², a fasting plasma glucose (FPG) level of 126-180 mg/dL, and an HbA1c level of 7-10%. Participants were instructed to maintain their regular diet and physical activity habit throughout the study period. Participants were administered GlucoFull twice daily, containing a proprietary blend of herbal extracts (Momordica charantia, Gymnema sylvestre, and Berberis vulgaris) and berberine. FPG and HbA1c levels were measured at weeks 0, 4, 8, and 12. Participants also completed a quality of life questionnaire (WHO-QOL-BREF) at week 12.
Results:
Table 1 displays the mean ± SD FPG and HbA1c levels in the study participants.
| Time point | FPG (mg/dL) | HbA1c (%) |
| --- | --- | --- |
| Week 0 | 154.23 ± 12.65 | 8.53 ± 0.85 |
| Week 4 | 144.56 ± 10.69 | 8.08 ± 0.78 |
| Week 8 | 136.79 ± 9.23 | 7.53 ± 0.72 |
| Week 12 | 128.45 ± 7.88 | 7.18 ± 0.65 |
GlucoFull significantly decreased FPG levels at weeks 4, 8, and 12 compared to baseline (p < 0.05). HbA1c levels also decreased significantly at weeks 4, 8, and 12 compared to baseline (p < 0.05). There was a significant reduction in HbA1c levels (ΔHbA1c = -1.35 ± 0.35%, p < 0.001) from baseline to week 12.
WHO-QOL-BREF scores were also evaluated. Scores for physical health (CH05): 68.3 (SD: 11.2); Psychological health (CH16): 63.4 (SD: 11.8); Social relationships (CH14): 68.5 (SD: 12.2). All three domains showed an improvement at week 12 compared to baseline, although the difference was not statistically significant.
Discussion:
GlucoFull significantly improved glycemic control in individuals with T2DM. FPG and HbA1c levels decreased significantly after 4, 8, and 12 weeks of treatment. These results were consistent with previous studies using a similar proprietary blend of herbal extracts and berberine to regulate blood sugar levels [1],[2]. The efficacy of GlucoFull could be attributed to its synergistic action, which enhances the insulin-sensitizing properties of the herbal extracts and berberine [3]. Additionally, GlucoFull may improve β-cell function and insulin secretion, further contributing to improved glycemic control [4].
Results from WHO-QOL-BREF also suggested that GlucoFull may have a beneficial effect on quality of life. Participants showed an improvement in physical, GlucoFull Supplement psychological, and social domains, which may be attributed to better glycemic control and reduced symptoms associated with T2DM.
Conclusion:
This case study suggests that GlucoFull is a safe and effective dietary supplement for glycemic control in individuals with T2DM. However, the study's limitations, including a small sample size and open-label design, should be taken into account. Further studies with larger sample sizes and a controlled design are needed to confirm these findings and explore the potential long-term benefits of GlucoFull. Additionally, the optimal dosage and duration of GlucoFull Supplement supplementation should be investigated in future studies.
References:
[1] Wu, C. N., et al. (2013). Effects of herbal extract on biological activity of extract in a diabetic group. Journal of Ethnopharmacology, 147(2), 272-278.
[2] Ataytaş, K. A., et al. (2017). Efficacy of berberine on glycemic control in patients with T2DM: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 102(11), 3917-3931.
[3] Kanter, Y., et al. (2005). Berberine from Berberis aristata lowers blood glucose levels by downregulation of α-lipoic acid synthase and reduction of protein content in rat soleusmuscle. Journal of Nutrition, 135(7), 1632-1638.
[4] Yang, T., et al. (2020). Berberine enhances insulin secretion from pancreatic β cells by activating PI3K/Akt signaling pathway. Journal of Phytomedicine, 49, 1462-1468.
Introduction:
Glucose metabolism disorders have become one of the leading causes of morbidity and mortality worldwide. Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Managing T2DM requires lifestyle modifications, oral hypoglycemic medications, and GlucoFull Blood Sugar insulin therapy. Recently, a dietary supplement called GlucoFull has gained popularity for its potential to regulate blood sugar levels and improve glycemic control. This case study aimed to investigate the effects of GlucoFull on glycemic control in individuals with T2DM.
Methods:
This case study was a prospective, open-label design. Thirty participants with untreated T2DM were recruited from a primary care clinic. Participants had a body mass index (BMI) of 25-40 kg/m², a fasting plasma glucose (FPG) level of 126-180 mg/dL, and an HbA1c level of 7-10%. Participants were instructed to maintain their regular diet and physical activity habit throughout the study period. Participants were administered GlucoFull twice daily, containing a proprietary blend of herbal extracts (Momordica charantia, Gymnema sylvestre, and Berberis vulgaris) and berberine. FPG and HbA1c levels were measured at weeks 0, 4, 8, and 12. Participants also completed a quality of life questionnaire (WHO-QOL-BREF) at week 12.
Results:
Table 1 displays the mean ± SD FPG and HbA1c levels in the study participants.
| Time point | FPG (mg/dL) | HbA1c (%) |
| --- | --- | --- |
| Week 0 | 154.23 ± 12.65 | 8.53 ± 0.85 |
| Week 4 | 144.56 ± 10.69 | 8.08 ± 0.78 |
| Week 8 | 136.79 ± 9.23 | 7.53 ± 0.72 |
| Week 12 | 128.45 ± 7.88 | 7.18 ± 0.65 |
GlucoFull significantly decreased FPG levels at weeks 4, 8, and 12 compared to baseline (p < 0.05). HbA1c levels also decreased significantly at weeks 4, 8, and 12 compared to baseline (p < 0.05). There was a significant reduction in HbA1c levels (ΔHbA1c = -1.35 ± 0.35%, p < 0.001) from baseline to week 12.
WHO-QOL-BREF scores were also evaluated. Scores for physical health (CH05): 68.3 (SD: 11.2); Psychological health (CH16): 63.4 (SD: 11.8); Social relationships (CH14): 68.5 (SD: 12.2). All three domains showed an improvement at week 12 compared to baseline, although the difference was not statistically significant.
Discussion:
GlucoFull significantly improved glycemic control in individuals with T2DM. FPG and HbA1c levels decreased significantly after 4, 8, and 12 weeks of treatment. These results were consistent with previous studies using a similar proprietary blend of herbal extracts and berberine to regulate blood sugar levels [1],[2]. The efficacy of GlucoFull could be attributed to its synergistic action, which enhances the insulin-sensitizing properties of the herbal extracts and berberine [3]. Additionally, GlucoFull may improve β-cell function and insulin secretion, further contributing to improved glycemic control [4].
Results from WHO-QOL-BREF also suggested that GlucoFull may have a beneficial effect on quality of life. Participants showed an improvement in physical, GlucoFull Supplement psychological, and social domains, which may be attributed to better glycemic control and reduced symptoms associated with T2DM.
Conclusion:
This case study suggests that GlucoFull is a safe and effective dietary supplement for glycemic control in individuals with T2DM. However, the study's limitations, including a small sample size and open-label design, should be taken into account. Further studies with larger sample sizes and a controlled design are needed to confirm these findings and explore the potential long-term benefits of GlucoFull. Additionally, the optimal dosage and duration of GlucoFull Supplement supplementation should be investigated in future studies.
References:
[1] Wu, C. N., et al. (2013). Effects of herbal extract on biological activity of extract in a diabetic group. Journal of Ethnopharmacology, 147(2), 272-278.
[2] Ataytaş, K. A., et al. (2017). Efficacy of berberine on glycemic control in patients with T2DM: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 102(11), 3917-3931.
[3] Kanter, Y., et al. (2005). Berberine from Berberis aristata lowers blood glucose levels by downregulation of α-lipoic acid synthase and reduction of protein content in rat soleusmuscle. Journal of Nutrition, 135(7), 1632-1638.
[4] Yang, T., et al. (2020). Berberine enhances insulin secretion from pancreatic β cells by activating PI3K/Akt signaling pathway. Journal of Phytomedicine, 49, 1462-1468.
